Screening Method for Agents Suitable for Therapy of Alzheimer's Disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a novel screening method for identifying therapeutic agents suitable for preventing or treating Alzheimer's disease. The method selects compounds that do not interfere with gamma-secretase activity or cause cell toxicity, reduce the production of the neurotoxic peptide Abeta42, and specifically bind to an APP-GxxxG motif, thereby weakening or inhibiting the dimerization of the APP transmembrane sequence. By targeting this mechanism, the method helps find drugs that could causally address the development of Alzheimer's disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Drug discovery and development for Alzheimer's disease therapies.
• High-throughput screening of compound libraries (natural or synthetic) to identify Alzheimer's treatment candidates.
• Lead optimization and structure-activity relationship studies focused on APP dimerization inhibition.
• Biotech and pharmaceutical companies seeking specific anti-Alzheimer's compounds.
• Research into the molecular mechanisms underlying Alzheimer's pathology.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a rational and causative approach to Alzheimer's disease therapy by targeting the root cause—the formation of Abeta42.
• Avoids interference with gamma-secretase's activity, thus minimizing side effects caused by broad inhibition of this enzyme.
• Selects for compounds with low or no cytotoxicity, increasing safety for therapeutic use.
• Targets and weakens APP dimerization, specifically reducing toxic Abeta42 formation while allowing normal processing of other substrates.
• Applicable to diverse libraries of molecules, including natural products and synthetic compounds, enhancing the likelihood of discovering novel therapeutics.
• Can be adapted for use in cell-free, cellular, or bacterial systems, increasing flexibility in drug screening assays.
• Potentially leads to disease-modifying Alzheimer's treatments rather than only symptomatic relief.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Described is a method of screening for therapeutic agents for the prophylaxis and therapy of Alzheimer's disease (AD), wherein agents that (i) do not interfere with the biological activity of gamma-secretase, (ii) do not exhibit cytotoxicity, (iii) lead to reduced amounts of Abeta42 and (iv) are capable of binding to an APP-GxxxG motif thereby weakening or inhibiting dimerization of the APP transmembrane sequence are suitable for prophylaxis or treatment of AD.